Abivax to Participate in Upcoming Fall Investor Conferences
Published on 11/02/2026 at 22:05 | dgap, AD HOC NEWS| ABIVAX / Key word(s): Conference 02.11.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences: Guggenheim Healthcare Innovation Conference Boston, Massachusetts November 9-11, 2026 Fireside Chat: Tuesday, November 10th, 10:30-10:55am ET LifeSci Capital X Sofinnova Growth & Innovation Summit London, United Kingdom November 16, 2026 30th German Equity Forum (Deutsches Eigenkapitalforum) Frankfurt, Germany November 23-25, 2026 Corporate Presentation: Monday, November 23rd, 11:40am-12:10pm CET Evercore ISI 9th Annual Healthcare Conference Miami, Florida November 30 – December 2, 2026 Fireside Chat: Wednesday, December 2nd, 7:55-8:15am ET Piper Sandler 38th Annual Healthcare Conference New York, New York December 1-3, 2026 Fireside Chat: Thursday, December 3rd, 8:00-8:25am ET Webcast links for select presentations will be available in the Investors section of Abivax’s website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company’s website for a limited time following the conference. About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Contact: Abivax SA Patrick Malloy SVP, Investor Relations patrick.malloy@abivax.com +1 847 987 4878 Media Contact: LifeSci Communications Karissa Baltz, PhD Associate Director LSC_ABIVAX@lifescicomms.com 02.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News |
en | FR0012333284 | ABIVAX | boerse | 70447660 |
